Presentations for Expert Practice in Pancreatic Cancer - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Presentations for Expert Practice in Pancreatic Cancer

Multidisciplinary Efforts to Improve Outcomes

Not a member of My prIME? Join now for instant access.

View downloadable slides from our 1.5-day live meeting addressing the treatment of patients with pancreatic cancer (PCA). This activity will help to enhance your understanding of PCA in order to provide optimal treatment strategies using standard as well as new/emerging agents.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Oct 30, 2019

Expiration Date

Oct 30, 2020

Featured Expert

  • Volker Ellenrieder, MD, PhD, University Hospital Gӧttingen, Gӧttingen, Germany

Featured Topic

PCA: New insights

Featured Expert

  • Maria Antonietta Bali, MD, PhD, Jules Bordet Institute, Free University of Brussels, Brussels, Belgium

Featured Topic

Challenges in diagnosis and staging of PCA

Featured Expert

  • Paolo G. Arcidiacono, MD, PhD, Vita Salute San Raffaele University, Milan, Italy

Featured Topic

Use of endoscopy for diagnosis and management of PCA

Featured Expert

  • Massimo Falconi, MD, University Vita-Salute San Raffaele, IRCCS San Raffaele Hospital, Milan, Italy

Featured Topic

Optimizing the role of surgery in the multimodality treatment of PCA

Featured Expert

  • Teresa Macarulla, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain

Featured Topic

Expanding (neo)adjuvant systemic treatment options for resectable PCA

Featured Expert

  • Carmen Rubio, MD, PhD, Hospital Clara Campal, Madrid, Spain

Featured Topic

Role of radiotherapy in localized PCA

Featured Expert

  • Praveen Peddu, MBBS, MRCS, FRCR, King's College Hospital, NHS Foundation Trust, London, United Kingdom

Featured Topic

Ablative therapies for inoperable locally advanced PCA

Featured Expert

  • Volker Ellenrieder, MD, PhD, University Hospital Gӧttingen, Gӧttingen, Germany

Featured Topic

Molecular testing to guide treatment in PCA: Is it ready for prime time?

Featured Expert

  • Teresa Macarulla, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain

Featured Topic

Targeting DNA damage repair defects

Featured Expert

  • Philip Agop Philip, MD, PhD, FRCP, Wayne State University and Karmanos Cancer Institute, Detroit, Michigan, United States

Featured Topic

Targeting PCA metabolism

Featured Expert

  • Eric Van Cutsem, MD, PhD, University Hospitals Leuven, Leuven, Belgium

Featured Topic

Targeting tumor microenvironment

Featured Expert

  • Thomas Seufferlein, MD, PhD , University of Ulm, Ulm, Germany

Featured Topic

prIME Points™ and closing remarks

This educational activity is designed for European gastroenterologists, surgical, radiation, and medical oncologists, and other healthcare providers involved in the management of patients with pancreatic cancer (PCA).

After successful completion of this educational activity, participants should be able to:

  • Explain the complex biology of PCA and the role of genomic profiling
  • Describe the state-of-the-art process for diagnosing and staging of PCA
  • Evaluate multimodality treatment strategies for resectable, borderline resectable, and locally advanced PCA, taking into account the latest data on (neo)adjuvant chemotherapy and local therapies
  • Select the most appropriate therapeutic sequencing for individual patients with metastatic PCA
  • Define novel treatment strategies evaluated in PCA, including therapies targeting DNA repair defects, cancer cell metabolism, and tumor microenvironment

This educational activity is supported by grants from Celgene, Erytech, and Rafael Pharmaceuticals.

Independent Medical Education (IME)

This IME activity is organized by prIME, a Medscape Oncology Company. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.

Provider

This activity is provided by prIME, a Medscape Oncology Company.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME, a Medscape Oncology Company assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME, a Medscape Oncology Company for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME, a Medscape Oncology Company is committed to providing its learners with high-quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Arcidiacono has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Bali has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Ellenrieder has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Falconi has disclosed receipt of grants/research support from Celgene, Ipsen, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Macarulla has disclosed receipt of honoraria for consultancy from Baxalta, Baxter, Bayer, Celgene, Genzyme Europe, Incyte, Ipsen, Lilly, QED Therapeutics, Roche, Sanofi, Servier, Shire Pharmaceuticals, and Tesaro. She has received support for travel or accommodation from Bayer, H3 Biomedecine, Merck, Sanofi, and Servier. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Peddu has disclosed receipt of honorarium from Angiodynamics for running IRE workshops. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Philip has disclosed that he has received grants/research support from Astellas, AstraZeneca, Bayer, BeiGene, Boston Biomedical, Bristol-Meyers Squibb, Celgene, Eli Lilly, Forty-Seven, Incyte, Isofol, Karyopharm, Merck, Novocure, Novartis, QED Therapeutics, Rafael Pharmaceuticals, Roche, Taiho, and Tyme. He has received honoraria or consultation fees from Bayer, Celgene, Merck, and TriSalus. He disclosed participation in company-sponsored speakers bureaus for Bayer, Bristol-Meyers Squibb, Celgene, Ipsen, and Merck. He disclosed membership on a data safety monitoring committee for Alsan, Blueprint, Erytech, and Lexicon. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Rubio has no relevant financial relationships to disclose. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Seufferlein has no financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Van Cutsem has disclosed receipt of grants/research support paid to his institution from Amgen, Bayer, Boehringer Ingelheim, Celgene, Ipsen, Lilly, Roche, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, and Servier. He has also received honoraria or consultation fees for advisory boards from AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Lilly, Merck Sharp & Dohme, Merck KGaA, Novartis, Roche, and Servier. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME, a Medscape Oncology Company have disclosed no relevant financial relationships.

CME Reviewer: Esther Nyarko, PharmD, Associate Director, Accreditation and Compliance
Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.